Hemolytic and biological assessment of lithium substituted hydroxyapatite nanoparticles for L929 and Hela cervical cancer cells

The improvement of performance and biological activity of bone substituted materials using nanotechnology is the main concern of dental and orthopedic surgery. Calcium orthophosphate-based biomaterials i.e. hydroxyapatite have a broad area of attractive biomedical implant operations. The current need for biomaterials implant surgery is bone substitute materials are characterized by biocompatibility, the good life of implants, bioactivity, there is not any post-surgery infections, good blood compatibility, all the mentioned properties are without the resistance or immune power loss is a big challenge for researchers and scientists. In the present investigation the synthesis, characterization, cell cytotoxicity, and blood compatibility of hydroxyapatite have been carried out. Enhancement of biocompatibility properties after incorporation of lithium in hydroxyapatite in physiochemical and biological conditions has been investigated. Lithium substituted hydroxyapatite samples were successfully synthesized by a modified solution combustion process with varying molar concentrations. X-ray diffraction (XRD) and transmittance electron microscopy (TEM) results confirm the structural and surface morphology of Li-HA nanoparticles, respectively. Two different cell lines i.e. L929 and Hela cervical cell lines were used for the biocompatibility of the Li-HA nanoparticles by using MTT assays for 12 and 24 h. The synthesized Li-HA is not only compatible with both cell lines but also is compatible with human blood and is plausible for further biomedical applications in orthopedic and dental applications.